| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11793796 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(13 years from now) | |
| US9884050 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(13 years from now) | |
| US10940142 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(13 years from now) | |
| US9907788 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(13 years from now) | |
| US11819496 | ARCUTIS | Topical roflumilast formulation having improved delivery and plasma half-life |
Jun, 2037
(13 years from now) | |
| US11129818 | ARCUTIS | Topical roflumilast formulation having improved delivery and plasma half life |
Aug, 2037
(13 years from now) | |
| US11707454 | ARCUTIS | Topical roflumilast formulation having antifungal properties |
Dec, 2041
(17 years from now) | |
Zoryve is owned by Arcutis.
Zoryve contains Roflumilast.
Zoryve has a total of 7 drug patents out of which 0 drug patents have expired.
Zoryve was authorised for market use on 15 December, 2023.
Zoryve is available in foam;topical dosage forms.
Zoryve can be used as topical treatment of seborrheic dermatitis in patients 9 years of age and older.
The generics of Zoryve are possible to be released after 03 December, 2041.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 15, 2026 |
Drugs and Companies using ROFLUMILAST ingredient
Market Authorisation Date: 15 December, 2023
Treatment: Topical treatment of seborrheic dermatitis in patients 9 years of age and older
Dosage: FOAM;TOPICAL
ZORYVE family patents
